Breaking News
Get 50% Off 0
Unlock Premium Data: Up to 50% Off InvestingPro CLAIM SALE
Close

Vertex Pharmaceuticals Inc (VRTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vertex's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
468.01 -3.37    -0.71%
21/06 - Closed. Currency in USD ( Disclaimer )
After Hours
470.57
+2.56
+0.55%
19:42:40 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,809,039
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 464.39 - 472.56
Vertex 468.01 -3.37 -0.71%

Vertex Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Vertex Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

4800

Equity Type

ORD

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Contact Information

Address 50 Northern Avenue
Boston, 02210
United States
Phone 617 341 6100
Fax -

Top Executives

Name Age Since Title
Bruce I. Sachs 62 1998 Lead Independent Director
Jeffrey Marc Leiden 66 2009 Executive Chairman
Reshma Kewalramani 49 2017 CEO, President & Director
Suketu P. Upadhyay 54 2022 Independent Director
Lloyd A. Carney 61 2019 Independent Director
Sangeeta N. Bhatia 55 2015 Independent Director
Diana Lynne McKenzie 59 2020 Independent Director
Nancy A. Thornberry 67 2023 Independent Director
Alan M. Garber 68 2017 Independent Director
Michel Lagarde 49 2023 Independent Director
Jennifer Schneider 48 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VRTX Comments

Write your thoughts about Vertex Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Feb 03, 2024 6:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The reason why people don't make it in crypto is because they haven't made a good decision towards their investments, this man has been the only one that has helped me out in some of my trade which has really helped me alot I pray God bless him and your family write him in wAsPP +31612574318)
Rakesh Patel
Rakesh Patel Jul 19, 2023 12:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i observe this stock last 1 year...  similarly i seen it's website....  product, what is going on mentioned in website.. story, company growth  etc.. so you shall  refer same as compare to stock price.  If growth story is excellent then stock will be good bounce back after 1,2,3, ..years...
Anisul Islam
Anisul Islam Jul 19, 2023 12:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vikas number 01781054242
Petet Larkar
Petet Larkar Apr 27, 2023 2:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great stock still good price ATH
Cardarius Lockett
Cardarius Lockett Dec 08, 2022 2:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thank for the Vibe and offer VRTX! I like to earn $319.92 for I can invest in to stock really bad
kay brown
kay brown Dec 08, 2022 2:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wow
Justan Oldguy
anoldguy Oct 24, 2022 8:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kathy Wood is selling, time to load up long!
RF RF
RF RF Feb 04, 2022 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks for the ride VRTX!
Дмитрий Счастливый
Дмитрий Счастливый Feb 02, 2022 11:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New moderna/ more shorts plz =))) --->295
Utónév vezetéknév
Utónév vezetéknév Jan 06, 2022 7:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Keeps this stock, rotation from tech growth to value stock is coming this year, I expect VRTX will benefit from this.
Nuno Santos
Nuno Santos Jan 06, 2022 7:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What a priceless tought. Safe money here in this actual cenario...
Vanessa Melchers
Vanessa Melchers Dec 22, 2021 4:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this is a most unexpected though long awaited bump. glad i held
David Garcia
David Garcia Dec 02, 2021 6:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
finally, it's moving, I'm holding this one from more than a year
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email